What is Topicals?
Founded in 2010, Topicals operates at the intersection of clinical efficacy and consumer-centric skincare. The company specializes in developing targeted solutions for chronic skin conditions, including eczema, hyperpigmentation, and psoriasis. By bridging the gap between medical-grade treatment and accessible beauty products, Topicals has carved out a distinct niche in the competitive personal care landscape. Its strategic partnership with Sephora serves as a primary distribution channel, validating the brand's appeal to a modern, informed consumer base seeking science-backed results for complex skin issues.
How much funding has Topicals raised?
Topicals has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2022): $10M with participation from Cavu Consumers Partners
Key Investors in Topicals
Cavu Consumers Partners
A venture capital firm specializing in high-growth consumer brands, focusing on companies that disrupt traditional retail categories through innovation and strong brand identity.
What's next for Topicals?
With the recent influx of capital, Topicals is poised to scale its operational capabilities and expand its product pipeline. The company is expected to leverage this financing to deepen its research and development efforts, potentially introducing new formulations that address a broader spectrum of dermatological needs. Furthermore, the strategic backing will likely facilitate enhanced marketing initiatives and supply chain optimization, ensuring that the brand maintains its competitive edge as it transitions from a high-growth startup to a more mature enterprise-level player in the global skincare market.
See full Topicals company page
